注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Alnylam Pharmaceuticals Inc是一家商業階段的生物製藥公司。該公司的商業產品和研究性核糖核酸(RNA)干擾(RNAi)治療劑的管線集中在四個戰略治療領域(STArs):基因藥物、心臟代謝疾病、肝臟傳染病和中樞神經系統/眼部疾病。該公司基於RNAi的藥物包括ONPATTRO(patisiran)、GIVLAARI(givosiran)、OXLUMO(lumasiran)和Leqvio(inclisiran)。ONPATTRO是一種針對甲狀腺素蛋白澱粉樣變性的靜脈注射RNAi治療藥物。GIVLAARI用於減少誘導的肝臟氨基乙酰丙酸合酶1mRNA,以減少與急性肝卟啉症(AHP)的發作和其他疾病表現相關的毒素。OXLUMO是一種靶向羥酸氧化酶1的RNAi療法,用於治療1型原發性高草酸尿症(PH1)。Leqvio用於治療成人高膽固醇血症。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Yvonne L. Greenstreet | 60 | 2016 | CEO & Director |
Paul R. Schimmel | 82 | 2002 | Member of the Scientific Advisory Board |
David P. Bartel | - | - | Member of Scientific Advisory Board |
Rachel Meyers | - | - | Member of Scientific Advisory Board |
Olivier Brandicourt | 67 | 2020 | Independent Director |
Dennis Arthur Ausiello | 78 | 2012 | Member of the Scientific Advisory Board & Independent Director |
Daniel J. Rader | - | - | Member of Scientific Advisory Board |
Michael W. Bonney | 65 | 2014 | Non-Independent Director |
Nancy J. Brown | - | 2015 | Member of Scientific Advisory Board |
Margaret A. Hamburg | 68 | 2019 | Independent Director |
Carolyn R. Bertozzi | 56 | 2023 | Independent Director |
Markus Stoffel | - | - | Member of Scientific Advisory Board |
Phillip A. Sharp | 78 | 2002 | Co-Founder, Member of the Scientific Advisory Board & Independent Director |
Priya S. Kishnani | - | 2020 | Member of the Scientific Advisory Board |
Charles Elliott Sigal | 71 | 2022 | Independent Director |
David E. I. Pyott | 71 | 2015 | Independent Director |
Colleen Foley Reitan | 64 | 2018 | Independent Director |
Akshay K. Vaishnaw | 61 | 2006 | Chief Innovation Officer & Member of the Scientific Advisory Board |
Amy W. Schulman | 63 | 2014 | Independent Chair of the Board & Lead Independent Director |
Muthiah Manoharan | 71 | 2003 | Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核